OUP user menu

Managing ST elevation myocardial infarction

F.J. Van de Werf, E.M. Antman, M.L. Simoons
DOI: http://dx.doi.org/10.1093/eurheartj/4.suppl_E.E15 E15-E23 First published online: 1 May 2002

Abstract

Fibrinolytic therapy has long been an important component of the treatment of patients with ST-elevation myocardial infarction (STEMI). Several new treatment strategies are currently being developed to improve the treatment of STEMI. These strategies include the development of new fibrinolytic agents that possess longer half-lives or increased fibrin specificity as compared with streptokinase or alteplase; combining fibrinolytic therapy with recently developed antiplatelet medications; and substitution of low-molecular weight heparins or other newer thrombin inhibitors for unfractionated heparin to improve the safety, convenience and efficacy of antithrombotic therapy.

  • Antiplatelet agents
  • fibrinolytic drugs
  • low-molecular-weight heparin
  • myocardial infarction